FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311193934> ?p ?o ?g. }

• W4311193934 endingPage "118" @default.
• W4311193934 startingPage "118" @default.
• W4311193934 abstract "Background: Tixagevimab/cilgavimab (TGM/CGM) are neutralizing monoclonal antibodies (mAbs) directed against different epitopes of the receptor-binding domain of the SARS-CoV-2 spike protein that have been considered as pre-exposure prophylaxis (PrEP). Objectives: This study seeks to assess the efficacy and safety of TGM/CGM to prevent COVID-19 in patients at high risk for breakthrough and severe SARS-CoV-2 infection who never benefited maximally from SARS-CoV-2 vaccination and for those who have a contraindication to SARS-CoV-2 vaccines. Design: This study is a systematic review and meta-analysis. The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement was followed. Methods: Electronic databases (PubMed, CINAHL, Embase, medRxiv, ProQuest, Wiley online library, Medline, and Nature) were searched from 1 December 2021 to 30 November 2022 in the English language using the following keywords alone or in combination: 2019-nCoV, 2019 novel coronavirus, COVID-19, coronavirus disease 2019, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2, tixagevimab, cilgavimab, combination, monoclonal, passive, immunization, antibody, efficacy, clinical trial, cohort, pre-exposure, prophylaxis, and prevention. We included studies in moderate to severe immunocompromised adults (aged ≥18 years) and children (aged ≥12 years) who cannot be vaccinated against COVID-19 or may have an inadequate response to SARS-CoV-2 vaccination. The effect sizes of the outcome of measures were pooled with 95% confidence intervals (CIs) and risk ratios (RRs). Results: Of the 76 papers that were identified, 30 articles were included in the qualitative analysis and 13 articles were included in the quantitative analysis (23 cohorts, 5 case series, 1 care report, and 1 randomized clinical trial). Studies involving 27,932 patients with high risk for breakthrough and severe COVID-19 that reported use of TGM/CGM combination were analyzed (all were adults (100%), 62.8% were men, and patients were mainly immunocompromised (66.6%)). The patients’ ages ranged from 19.7 years to 79.8 years across studies. TGM/CGM use was associated with lower COVID-19-related hospitalization rate (0.54% vs. 1.2%, p = 0.27), lower ICU admission rate (0.6% vs. 5.2%, p = 0.68), lower mortality rate (0.2% vs. 1.2%, p = 0.67), higher neutralization of COVID-19 Omicron variant rate (12.9% vs. 6%, p = 0.60), lower proportion of patients who needed oxygen therapy (8% vs. 41.2%, p = 0.27), lower RT-PCR SARS-CoV-2 positivity rate (2.1% vs. 5.8%, p < 0.01), lower proportion of patients who had severe COVID-19 (0% vs. 0.5%, p = 0.79), lower proportion of patients who had symptomatic COVID-19 (1.8% vs. 6%, p = 0.22), and higher adverse effects rate (11.1% vs. 10.7%, p = 0.0066) than no treatment or other alternative treatment in the prevention of COVID-19. Conclusion: For PrEP, TGM/CGM-based treatment can be associated with a better clinical outcome than no treatment or other alternative treatment. However, more randomized control trials are warranted to confirm our findings and investigate the efficacy and safety of TGM/CGM to prevent COVID-19 in patients at risk for breakthrough or severe SARS-CoV-2 infection." @default.
• W4311193934 created "2022-12-24" @default.
• W4311193934 creator A5002696886 @default.
• W4311193934 creator A5008187666 @default.
• W4311193934 creator A5009407017 @default.
• W4311193934 creator A5014593593 @default.
• W4311193934 creator A5014770928 @default.
• W4311193934 creator A5021855598 @default.
• W4311193934 creator A5022201674 @default.
• W4311193934 creator A5032154927 @default.
• W4311193934 creator A5035830011 @default.
• W4311193934 creator A5037216399 @default.
• W4311193934 creator A5037373281 @default.
• W4311193934 creator A5052045732 @default.
• W4311193934 creator A5058134852 @default.
• W4311193934 creator A5058720193 @default.
• W4311193934 creator A5073053820 @default.
• W4311193934 creator A5079725698 @default.
• W4311193934 creator A5088047025 @default.
• W4311193934 date "2022-12-01" @default.
• W4311193934 modified "2023-10-01" @default.
• W4311193934 title "Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis" @default.
• W4311193934 cites W1967046314 @default.
• W4311193934 cites W2005501262 @default.
• W4311193934 cites W2157823046 @default.
• W4311193934 cites W2567362164 @default.
• W4311193934 cites W2752005892 @default.
• W4311193934 cites W2801386437 @default.
• W4311193934 cites W2970684805 @default.
• W4311193934 cites W2978795816 @default.
• W4311193934 cites W3019953082 @default.
• W4311193934 cites W3042323010 @default.
• W4311193934 cites W3048226591 @default.
• W4311193934 cites W3094167898 @default.
• W4311193934 cites W3128795415 @default.
• W4311193934 cites W3128847099 @default.
• W4311193934 cites W3155123963 @default.
• W4311193934 cites W3156249792 @default.
• W4311193934 cites W3157917808 @default.
• W4311193934 cites W3164655641 @default.
• W4311193934 cites W3180943617 @default.
• W4311193934 cites W3190398149 @default.
• W4311193934 cites W4220970752 @default.
• W4311193934 cites W4221019888 @default.
• W4311193934 cites W4221072241 @default.
• W4311193934 cites W4223551102 @default.
• W4311193934 cites W4226525051 @default.
• W4311193934 cites W4280500643 @default.
• W4311193934 cites W4281264056 @default.
• W4311193934 cites W4281291757 @default.
• W4311193934 cites W4281389914 @default.
• W4311193934 cites W4281395427 @default.
• W4311193934 cites W4281739426 @default.
• W4311193934 cites W4281806278 @default.
• W4311193934 cites W4281911014 @default.
• W4311193934 cites W4283031889 @default.
• W4311193934 cites W4283078012 @default.
• W4311193934 cites W4283208961 @default.
• W4311193934 cites W4283319609 @default.
• W4311193934 cites W4283327493 @default.
• W4311193934 cites W4285008916 @default.
• W4311193934 cites W4285388425 @default.
• W4311193934 cites W4286009139 @default.
• W4311193934 cites W4286255972 @default.
• W4311193934 cites W4287306898 @default.
• W4311193934 cites W4287959727 @default.
• W4311193934 cites W4288704106 @default.
• W4311193934 cites W4289171764 @default.
• W4311193934 cites W4291432422 @default.
• W4311193934 cites W4292210076 @default.
• W4311193934 cites W4293330399 @default.
• W4311193934 cites W4296293045 @default.
• W4311193934 cites W4296489353 @default.
• W4311193934 cites W4298007826 @default.
• W4311193934 cites W4306146990 @default.
• W4311193934 cites W4306672755 @default.
• W4311193934 cites W4307705785 @default.
• W4311193934 cites W4307775680 @default.
• W4311193934 cites W4308339823 @default.
• W4311193934 cites W4309166972 @default.
• W4311193934 doi "https://doi.org/10.3390/diseases10040118" @default.
• W4311193934 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36547204" @default.
• W4311193934 hasPublicationYear "2022" @default.
• W4311193934 type Work @default.
• W4311193934 citedByCount "8" @default.
• W4311193934 countsByYear W43111939342023 @default.
• W4311193934 crossrefType "journal-article" @default.
• W4311193934 hasAuthorship W4311193934A5002696886 @default.
• W4311193934 hasAuthorship W4311193934A5008187666 @default.
• W4311193934 hasAuthorship W4311193934A5009407017 @default.
• W4311193934 hasAuthorship W4311193934A5014593593 @default.
• W4311193934 hasAuthorship W4311193934A5014770928 @default.
• W4311193934 hasAuthorship W4311193934A5021855598 @default.
• W4311193934 hasAuthorship W4311193934A5022201674 @default.
• W4311193934 hasAuthorship W4311193934A5032154927 @default.
• W4311193934 hasAuthorship W4311193934A5035830011 @default.
• W4311193934 hasAuthorship W4311193934A5037216399 @default.
• W4311193934 hasAuthorship W4311193934A5037373281 @default.

• next